Role of Corticotropin-Releasing Factor (CRF) Receptor-1 on the Catecholaminergic Response to Morphine Withdrawal in the Nucleus Accumbens (NAc)

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Almela, Pilar ^a   Navarro Zaragoza, Javier ^a   García Carmona, Juan Antonio ^a   Mora, Lucía ^a   Hidalgo, Juana ^a   Milanés, María Victoria ^a   Laorden, María Luisa ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE; MORPHINE; NALOXONE; NORADRENALIN; SERINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN FUNCTION; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; HORMONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RAT; REWARD; VENTRAL TEGMENTUM; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANIMALS; CORTICOSTERONE; DOPAMINE; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NEURONS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SERINE; SUBSTANCE WITHDRAWAL SYNDROME; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84867347181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047089     Document Type: Article

References (66)

1. Koob GF, (2008) A role for brain stress systems in addiction. Neuron 59: 11-34.
2. Piazza PV, Le Moal M, (1998) The role of stress in drug self-administration. Trends Pharmacol Sci 19: 67-74.
3. Sinha R, (2008) Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 1141: 105-130.
4. Goeders NE, Guerin GF, (2000) Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neurophsychopharmacology 23: 577-586.
5. Piaza PV, Le Moal ML, (1996) Pathophysiological basis of vulnerability to drug abuse: Role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu Rev Pharmacol Toxicol 36: 359-378.
6. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G, (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403: 430-434.
7. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F, (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054.
8. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, et al. (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428: 191-212.
9. Korossi A, Veening JG, Kozicz T, Henckens M, Dederen J, et al. (2006) Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res 1072: 46-54.
10. Koob GF, (2010) The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14.
11. Laorden ML, Fuertes G, González-Cuello A, Milanés MV, (2000) Changes in catecholaminergic pathways innervating paraventricular nucleus and pituitary-adrenal axis response during morphine dependence: Implication of alpha1 and alpha2 adrenoreceptors. J Pharmacol Exp Ther 293: 578-584.
12. Laorden ML, Nuñez C, Almela P, Milanés MV, (2002) Morphine withdrawal-induced c-Fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones. J Neurochem 83: 132-140.
13. Koob GF, (1999) Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46: 1167-1180.
14. Stinus L, Cador M, Zorrilla EP, Koob GF, (2005) Buprenorphine and CRF1R antagonists block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30: 90-98.
15. Carlezon WA, Thomas MJ, (2009) Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis. Neurophamacology 56: 122-132.
16. Koob GF, Le Moal M, (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
17. Di Chiara G, North AR, (1992) Neurobiology of opiate abuse. Trends Pharmacol Sci 13: 185-193.
18. Roesch MR, Calu DJ, Schoenbaum G, (2007) Dopamine neurons encode the better option in rats deciding between differently delayed or sized rewards. Nat Neurosci 10: 1615-1624.
19. Schultz W, (2007) Multiple dopamine functions at different time courses. Annu Rev Neurosci 30: 259-288.
20. Matsumoto M, Hikosaka O, (2009) Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 459: 837-841.
21. Sinha R, (2001) How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 158: 343-359.
22. Erb S, Shaham Y, Stewart J, (1996) Stress reinstates cocaine seeking behaviour after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 128: 408-412.
23. Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ, (1989) Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontalcortex. J Neurochem 52: 1655-1658.
24. Inglis FM, Moghaddam B, (1999) Dopaminergic innervations of the amygdala is highly responsive to stress. J Neurochem 72: 1088-1094.
25. McFarland K, Davidge SB, Lapish CC, Kalivas PW, (2004) Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behaviour. J Neurosci 24: 1551-1560.
26. Tidey JW, Miczek KA, (1996) Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res 721: 140-149.
27. Wang B, Shaham Y, Zitzman D, Azari S, Wise RA, et al. (2005) Cocaine experience establishes control of midbrain glutamate and dopamine by corticotrophin-releasing factor: a role in stress -induced relapse to drug seeking. J Neurosci 25: 5389-5396.
28. Wanat MJ, Hofp EW, Stuber GD, Phillips PEM, Bonci A, (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol 586: 2157-2170.
29. Nuñez C, Földes A, Pérez-Florez D, García-Borrón JC, Laorden ML, et al. (2009) Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase (TH)mRNA expression, phosphorylation and enzyme activity in the nucleus of the solitary tract (NTS-A2) during morphine withdrawal. Endocrinology 150: 3118-3127.
30. Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P, (2008) Synaptic physiology of central CRH system. Eur J Pharmacol 583: 215-225.
31. Zorrilla EP, Koob GF, (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13: 799-828.
32. Contarino A, Papaleo F, (2005) The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 102: 18649-18654.
33. Navarro-Zaragoza J, Nuñez C, Laorden ML, Milanés MV, (2010) Effects of corticotrophin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal. Mol Pharmacol 77: 864-873.
34. Papaleo F, Kitchener P, Contarino A, (2007) Disruption of the CRF/CRF1 receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 53: 577-589.
35. Fuertes G, Laorden ML, Milanés MV, (2000) Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology 71: 60-67.
36. Nuñez C, Castells MT, Laorden ML, Milanés MV, (2008) Regulation of extracellular signal-regulated kinases (ERKs) by naloxone-induced morphine withdrawal in the brain stress system. Naunyn-Schmiedeberg's Arch Pharmacol 378: 407-420.
37. Skelton KH, Oren D, Gutman DA, Easterling K, Holtzman SG, et al. (2007) The CRF1 receptor antagonist, R121919 attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacol 571: 17-24.
38. Zobel AW, Nickel T, Küazel HE, Ackl N, Sonntag A, et al. (2000) Effects of the high-affinity corticotrophin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181.
39. Tilders FJ, Berkenbosch F, Vermes I, Linton EA, Smelek PG, (1985) Role of epinephrine and vasopressin the control of the pituitary-adrenal response to stress. Fed Proc 44: 155-168.
40. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, et al. (1999) The impact of the nonpeptide corticotrophin-releasing hormone antagonist antalarmin on behavioural and endocrine responses to stress. Endocrinology 140: 79-86.
41. Leknes S, Tracey I, (2008) A common neurobiology for pain and pleasure. Nat Rev Neurosci 9: 314-320.
42. Montague PR, Hyman SE, Cohen JD, (2004) Computational roles for dopamine in behavioural control. Nature 431: 760-767.
43. Schultz W, (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80: 1-27.
44. Ungless MA, (2004) Dopamine: the salient issue. Trends Neurosci 27: 702-706.
45. Ungless MA, Magill PJ, Bolam JP, (2004) Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303: 2040-2042.
46. Brischoux F, Chakraborty S, Brierley DI, Ungless MA, (2009) Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc Natl Acad Sci USA 106: 4894-4899.
47. Wang DV, Tsien JZ, (2011) Convergent processing of both positive and negative motivational signals by the VTA dopamine neuronal populations. PLoS One 6: e17047.
48. Zweifel LS, Fadok JP, Argilli E, Garelick MG, Jones GL, et al. (2011) Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat. Neurosci 14: 620-626.
49. Budygin EA, Park J, Bass CE, Grinevich VP, Bonin KD, et al. (2012) Aversive stimulus differentially triggers subsecond dopamine release in reward regions. Neurosci 201: 331-337.
50. Rosseti ZL, Hmaidan Y, Gessa GL, (1992) Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221: 227-234.
51. Diana M, Pistis M, Muntoni A, Gessa G, (1995) Profound decrease of mesolimbic dopaminergic neuronal activity in morphine-withdrawn rats. J Pharmacol Exp Ther 272: 781-785.
52. Mazei-Robison MS, Koo JW, Friedman AK, Lansink CA, Robison AJ, et al. (2011) Role for mTOR signalling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron 72: 977-990.
53. Sauvage M, Steckler T, (2001) Detection of corticotrophin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei: potential implication for arousal and attention. Neuroscience 104: 643-652.
54. Smith RJ, Aston-Jones G, (2008) Noradrenergic transmission in the extended amygdale: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213: 43-61.
55. Aston-Jones G, Kalivas PW, (2008) Brain norepinephrine rediscovered in addiction research. Biol. Psychiatry 63: 1005-1006.
56. Garcia-Carmona JA, Almela P, Baroja-Mazo A, Milanés MV, Laorden ML, (2011) Restricted role of CRF1 receptor for the activity of brainstem catecholaminergic neurons in the negative state of morphine withdrawal. Psychopharmacology 220: 379-393.
57. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW, (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91: 1025-1043.
58. Lu L, Liu Z, Huang M, Zhang Z, (2003) Dopamine-dependent responses to cocaine depend on corticotrophin-releasing factor receptor subtypes. J Neurochem 84: 1378-1386.
59. Salvatore MF, García-España A, Goldstein M, Deutch AY, Harykock JW, (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J Neurochem 75: 225-232.
60. Riegel AC, Williams JT, (2008) CRF facilitates calcium release from intracellular stores in midbrain dopamine neurons. Neuron 57: 559-570.
61. Ungless MA, Singh V, Crowder TL, Yaka R, Ron D, et al. (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39: 401-407.
62. Frenois F, Cador M, Caille S, Stinus L, Moine C, (2002) Neural correlation of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377-1389.
63. Gold LH, Stinus L, Inturrisi CE, Koob GF, (1994) Prolonged tolerance, dependence, and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol 253: 45-51.
64. Berhow MT, Russel DS, Terwilliger RZ, Beitner-Johnson D, Self DW, et al. (1995) Influence of neurotrophic factors on morphine - and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neurosci 68: 969-979.
65. Wiechelman KJ, Braun RD, Fitpatrick JD, (1988) Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175: 231-237.
66. Nuñez C, Laorden ML, Milanés MV, (2007) Regulation of Serine (Ser)-31 and Ser40 tyrosine hydroxylase phosphorylation during morphine withdrawal in the hypothalamic paraventricular nucleus and nucleus tractus solitarius-A2 cell group. Role of ERK1/2. Endocrinology 148: 5780-5793.